Director at Korro Bio (NASDAQ: KRRO) awarded stock options for 14,677 shares

Rhea-AI Filing Summary

Korro Bio director Jean Francois Formela received a stock option grant as equity compensation. The award covers 14,677 shares of common stock at an exercise price of $10.59 per share and expires on June 9, 2036. The option vests in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving as a non-employee director through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FORMELA JEAN FRANCOIS

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,677	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 14,677 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 14,677 shares Exercise price: $10.59 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option shares granted 14,677 shares Stock Option (Right to Buy) grant to director

Exercise price $10.59 per share Conversion or exercise price for the option

Expiration date June 9, 2036 Option term end date

Total derivative shares after grant 14,677 shares Stock options held following the transaction

Vesting trigger 1 year or next annual meeting Earlier of one-year anniversary or next stockholder meeting

Key Terms

Stock Option (Right to Buy), exercise price, non-employee director, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "10.5900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

non-employee director financial

"subject to continued service as a non-employee director through the applicable vesting date"

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders, subject to continued service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FORMELA JEAN FRANCOIS

(Last) (First) (Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.59	06/10/2026		A		14,677		(1)	06/09/2036	Common Stock	14,677	$0	14,677	D

Explanation of Responses:

1. The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.

	/s/ Jeffrey Cerio, attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Korro Bio (KRRO) director Jean Francois Formela report on this Form 4?

Jean Francois Formela reported receiving a stock option grant for 14,677 shares of Korro Bio common stock. The option is a compensation award, not an open-market purchase, and gives him the right to buy shares at a fixed exercise price.

How many Korro Bio (KRRO) shares are covered by Formela’s new stock option?

The stock option grant covers 14,677 shares of Korro Bio common stock. This entire amount is reflected as derivative securities owned following the transaction, showing his new options position from this single grant event.

What is the exercise price and expiration date of Formela’s Korro Bio option grant?

The option has an exercise price of $10.59 per share and expires on June 9, 2036. This means he can choose to buy up to 14,677 shares at $10.59 any time before that expiration, once vested.

When do Jean Francois Formela’s Korro Bio options vest?

The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders. Vesting requires his continued service as a non-employee director through the applicable vesting date.

Is this Korro Bio (KRRO) Form 4 an insider purchase or a compensation award?

This Form 4 reports a compensation-related stock option award, coded as an acquisition (A) for grant or award. It does not reflect an open-market share purchase or sale, but rather an option grant from the company to a director.